Clinical Trials
10 trialsNCT02297438 2026-05-14
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer
Phase 3 Completed
NCT03784014 2026-04-29
MULTISARC
Institut National de la Santé Et de la Recherche Médicale, France
Phase 3 Completed
NCT03079011 2025-11-18
PADA-1
UNICANCER
Phase 3 Completed
NCT01740427 2024-11-14
PALOMA-2
Pfizer
Phase 3 Completed
NCT02028507 2024-09-25
PEARL
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT01942135 2024-04-04
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
Pfizer
Phase 3 Completed
NCT01864746 2023-12-12
PENELOPE-B
GBG Forschungs GmbH
Phase 3 Completed
NCT03447132 2023-03-10
SAFIA
International Cancer Research Group, United Arab Emirates
Phase 3 Completed
NCT03969121 2023-03-10
Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
Kyoto Breast Cancer Research Network
Phase 3 Completed
NCT02600923 2022-01-20
Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate
Pfizer
Phase 3 Completed